JW Chongwoo Pharmaceutical 'Newment Premium B' (Photo by JW Chongwoo Pharmaceutical)

JW Chongwoo Pharmaceutical 'Newment Premium B' (Photo by JW Chongwoo Pharmaceutical)

View original image

[Asia Economy Reporter Chunhee Lee] The most essential nutrient for modern people experiencing chronic fatigue is vitamin. In particular, chronic fatigue is a representative symptom that occurs when the vitamin B1 group is deficient in the body. Vitamin B1, commonly known as 'thiamine,' is essential for nerve and muscle activity, involved in energy metabolism and nucleic acid synthesis. Since nucleic acids contribute to promoting metabolism, preventing dementia, and improving liver function, vitamin B1, which is necessary for their synthesis, is the most important among the B vitamins.


Among the active forms of vitamin B1, the two most notable are ‘pyridoxal thiamine’ and ‘benfotiamine.’ JW Pharmaceutical’s 'Newment Premium B' is a product that contains both pyridoxal thiamine, which crosses the blood-brain barrier to deliver thiamine to nerves, and benfotiamine, which is rapidly absorbed by the body and has a long-lasting effect.


Pyridoxal thiamine quickly supplies thiamine to the brain, making it necessary for students under a lot of stress or office workers at risk of alcoholic diseases due to frequent social drinking. Benfotiamine, on the other hand, has higher bioavailability than other thiamine forms and quickly replenishes thiamine deficiency throughout the body except for the brain. This makes it suitable for modern people who are physically fatigued or require a lot of exercise energy.



A JW Pharmaceutical official said, "While multivitamins and vitamin C have dominated the vitamin market, recently, there is a trend recommending customized vitamin intake," adding, "The popularity of vitamin B group among modern people who are tired and stressed is the same phenomenon."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing